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Abstract
Background: JCV is a DNA polyomavirus very well adapted to humans. Although JCV DNA has been detected in colorectal
cancers (CRC), the association between JCV and CRC remains controversial. In China, the presence of JCV infection in CRC
patients has not been reported. Here, we investigated JCV infection and viral DNA load in Chinese CRC patients and to
determine whether the JCV DNA in peripheral blood (PB) can be used as a diagnostic marker for JCV-related CRC.
Methodology/Principal Findings: Tumor tissues, non-cancerous tumor-adjacent tissues and PB samples were collected
from 137 CRC patients. In addition, 80 normal colorectal tissue samples from patients without CRC and PB samples from 100
healthy volunteers were also harvested as controls. JCV DNA was detected by nested PCR and glass slide-based dot blotting.
Viral DNA load of positive samples were determined by quantitative real-time PCR. JCV DNA was detected in 40.9% (56/137)
of CRC tissues at a viral load of 49.1 to 10.3610
4 copies/mg DNA. Thirty-four (24.5%) non-cancerous colorectal tissues (192.9
to 4.4610
3 copies/mg DNA) and 25 (18.2%) PB samples (81.3 to 4.9610
3 copies/mg DNA) from CRC patients were positive for
JCV. Tumor tissues had higher levels of JCV than non-cancerous tissues (P=0.003) or PB samples (P,0.001). No correlation
between the presence of JCV and demographic or medical characteristics was observed. The JCV prevalence in PB samples
was significantly associated with the JCV status in tissue samples (P,0.001). Eleven (13.8%) normal colorectal tissues and
seven (7.0%) PB samples from healthy donors were positive for JCV.
Conclusions/Significance: JCV infection is frequently present in colorectal tumor tissues of CRC patients. Although the
association between JCV presence in PB samples and JCV status in tissue samples was identified in this study, whether PB
JCV detection can serve as a marker for JCV status of CRC requires further study.
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Introduction
The John Cunningham virus (JCV) is a ubiquitous, small, non-
enveloped polyomavirus with a closed, circular, double-stranded
DNA genome that frequently resides in the kidneys of healthy
individuals and is excreted in the urine of a large portion of the
adult population. JCV infection is subclinical and leads to lifelong
latency, but may be reactivated when the immune system is
impaired [1–3]. JCV is associated with disease primarily in
immunocompromised individuals and its replication in glial cells
could lead to progressive multifocal leukoencephalopathy (PML),
an often fatal disease of central nervous system [4]. Like other
polyomaviruses, JCV encodes a version of a large T-antigen that
can bind to and inactivate tumor suppressor proteins p53 and pRB
and interfere with several cell-signaling pathways [5–7]. Moreover,
JCV genomic DNA sequences and T-antigen expression have
been detected in a broad range of human tumor cell types
including oligodendrocytes, astrocytomas, glioblastomas, ependy-
momas, and most other types of brain tumors [8], indicating that
JCV infection may be associated with human carcinogenesis.
More recently, JCV was also found in non-neural cancers, such
as gastric [9] and lung cancers [10]. JCV infection was first
reported as a potential risk factor for colorectal cancer (CRC) in
a work by Laghi et al. [11], which found that 96% of CRC tissues
were positive for JCV DNA sequences. Subsequently, other studies
have been published showing that JCV sequences were found in
26%–88.9% of CRC tissues, with sample sizes ranging from 18 to
105 [12–15]. In contrast, other studies have subsequently shown
that no detectable JCV DNA was present in colorectal tissues
indicating no association between JCV and colon neoplasia [16–
17]. JCV prevalence in various CRC sample sets may be due to
differences in assay sensitivities across studies, contamination
between samples, or geographic locations of the selected popula-
tion. Although demonstration of the presence of the tumor viral
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carcinogenesis, additional evidence, such as high viral load, is
necessary to support a causal role. However, only two studies have
mentioned the viral load of JCV in CRC [11,15]. Considering the
controversial reports on the etiology of JCV in CRC, it appears
that the association between JCV infection and CRC needs to be
further investigated.
Many studies have demonstrated that JCV DNA or antigens
can be detected in the peripheral blood (PB) or serum. Viral
components detected in the blood have historically been presumed
to have originated from metastasized cancer cells or from virus-
containing cellular debris shed from a local infection site [18].
Although two prospective case-control studies have been per-
formed to determine the association between JCV seropositivity
and CRC development [19–20], there has been no report
describing the presence of JCV DNA in the blood of CRC
patients published to date. In this study, we investigated the
prevalence of JCV in Chinese CRC patients to determine
a potential relationship. In addition, we investigated whether
JCV DNA in PB is suitable as a diagnostic marker for JCV-related
CRC.
Methods
Ethics statement
This project was approved by the Ethics Committee of the First
Affiliated Hospital, College of Medicine, Zhejiang University,
Hangzhou, China. Written informed consent was provided by
patients and controls.
Clinical samples
All clinical samples were obtained between May 2007 and
October 2011 from patients admitted to the First Affiliated
Hospital, College of Medicine, Zhejiang University (Hangzhou,
China). Tumor tissues, non-cancerous tumor-adjacent tissues and
PB samples from 137 random CRC patients (mean patient age,
62.99; range, 27–86 years) were collected less than three months
after CRC diagnosis. Patients undergoing surgery for recurrences
were excluded. Non-cancerous tumor-adjacent tissue was collected
from an area ,15 cm distal from the tumor. In addition, 80
colorectal tissues from non-pathologic mucosa of patients un-
dergoing colonoscopy for evaluation of functional disorders such
as diarrhea or constipation unrelated to cancer or inflammatory
bowel disease (IBD) and 100 PB samples from healthy donors
upon physical examination with no history of cancer or polyp
diagnosis were collected as controls. Tissue samples were divided;
one part was kept for histopathological analysis, and the other
transferred to cryotubes, immediately frozen in liquid nitrogen,
and stored at 2196uC for further analysis. All sample data were
recorded in a sample collection database.
DNA extraction
About 50 mg of each tissue sample was homogenized in a 2 ml
sterile tube with 1 ml of 0.09% sodium chloride solution using an
electric homogenizer (PRO Scientific, Oxford, CT, USA). To
minimize cross-contamination between samples, the probe was
washed in fresh sterile water three times, 40% hydrogen peroxide
solution twice, 75% ethanol twice and heated in a 95% ethanol
burner for 3 min between samples. Four hundred microliters of
each PB sample was used for DNA isolation. The DNA of each
sample was extracted using the MasterPure DNA Purification Kit
(Epicentre Biotechnologies, Madison, WI, USA) according to the
manufacturer’s instruction. To confirm the integrity of DNA
extracted, PCR using glyceraldehydes phosphate dehydrogenase
(GAPDH) primers was undertaken as described previously [21].
Table 1. Demographic characteristics of CRC patients (C), non-CRC patients (N) and healthy donors (H).
Characteristic
CRC patients
n=137
Non-CRC patients
n=80
Healthy donors
n=100 P Cv sN P Cv sH
Age (mean 6 SD) 63.0612.6 49.6613.3 62.6613.1 ,0.001 0.817
Sex 0.940 0.985
Male 74 (54.0)
c 44 (55.0) 56 (56.0)
Female 63 (46.0) 36 (45.0) 44 (44.0)
Tobacco exposure
a 0.922 0.998
Yes 44 (32.1) 27 (33.8) 33 (33.0)
No 93 (67.9) 53 (66.2) 67 (67.0)
Alcohol use
b 0.785 0.859
Yes 29 (21.2) 19 (23.8) 23 (23.0)
No 108 (78.8) 61 (76.2) 77 (77.0)
Residence 0.7557 0.511
City 71 (51.8) 44 (55.0) 57 (57.0)
Country 66 (48.2) 36 (45.0) 43 (43.0)
Family history of CRC 0.491 0.162
Yes 27 (19.7) 12 (15.0) 11 (11.0)
No 110 (80.3) 68 (85.0) 89 (89.0)
a, No tobacco exposure was defined as never having smoked cigarettes daily for more than 1 year.
b, No alcohol use was defined as never having consumed 1 drink or more per month.
c, Values within parentheses indicate percentages.
doi:10.1371/journal.pone.0035900.t001
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Nested PCR amplification was performed using a set of primers
for T-antigen as described previously [13]. Briefly, the 173 bp
target of JCV T-antigen was first amplified by using of the primers
JCT-1F (59-AGT CTT TAG GGT CTT CTA-39) and JCT-1R
(59-GGT GCC AAC CTA TGG AAC AG-39). First round PCR
condition was denatured at 95uC for 10 min, followed by 30 cycles
of denaturation at 95uC for 15 s, annealing at 55uC for 30 s and
extension at 72uC for 30 s. Nested PCR was performed by using
2 ml of the first-round product as a template, with the primers
JCT-1F and JCT-2R (59-TGA AGA CCT GTT TTG CCA TG-
39). The nested PCR condition was denatured at 95uC for 10 min,
followed by 30 cycles of denaturation at 95uC for 15 s, annealing
at 60uC for 30 s and extension at 72uC for 30 s. The nested PCR
procedure amplified a 110 bp target sequence. To avoid potential
PCR false-positive results, two water controls were included for
first round PCR and nested PCR. If either control of the two water
controls yielded a false-positive in the nested PCR, the whole set of
PCR and nested PCR was restarted with new reagent. For each
sample, 1 ml of DNA was amplified by nested PCR. Four
microliters of each amplification products were analyzed by
electrophoresis on 2% agarose gel and ethidium bromide staining.
Glass slide-based dot blotting
The nested-PCR products were purified with MinElute PCR
Purification Kit (QIAGEN, Hilton, Germany) and finally eluted in
10 ml EB buffer (10 mM Tris-Cl, pH 8.5). Purified DNA samples
were mixed with one volume of DMSO, and spotted onto surfaces
of aminosilane slides (CapitalBio, Beijing, China) as three
replicates with a SmartArrayer spotter (CapitalBio, Beijing,
China). After baking for 1 h at 80uC, the slides were rinsed in
0.2% SDS for 5 min and cleaned by washing with ddH2O.
TAMRA-labeled oligonucleotide probe (JCT-probe, 59-GTT
Figure 1. Detection of the JCV T-antigen sequence in samples
from CRC patients. (A) The 110 bp fragment was amplified from DNA
isolated from matched samples of colorectal cancer (upper) and normal
tumor adjacent tissues (lower) with nested PCR. M: DL 2,000 DNA
Marker (TaKaRa); P: positive control; N1: first-round negative control; N2:
second-round negative control. (B) Images from JCV nested-PCR
product arrays. Nested-PCR products of tumor tissues (left) and normal
tumor adjacent tissues (right) were spotted onto surfaces of
aminosilane slides as three replicates, hybridized with TAMRA-labeled
oligonucleotide probe and finally visualized by AXON scanner. (C) The
numbers of JCV-positive samples in 137 matched pairs of tumor tissue,
non-cancerous adjacent tumor tissue and PB samples from CRC
patients.
doi:10.1371/journal.pone.0035900.g001
Table 2. Factors associated with JCV infection among CRC
patients.
Characteristic
JCV-positive
n (%)
JCV-negative
n (%) P
Age (mean 6 SD) 64.2613.0 61.8612.3 0.261
Sex 0.438
Male 39 (53.4) 34 (46.6)
Female 29 (45.3) 35 (54.7)
Tobacco exposure
a 0.330
Yes 25 (56.8) 19 (43.2)
No 43 (46.2) 50 (53.8)
Alcohol use
b 0.708
Yes 13 (44.8) 16 (55.2)
No 55 (50.9) 53 (49.1)
Residence 0.929
City 36 (50.7) 35 (49.3)
Country 32 (48.5) 34 (51.5)
Family history of CRC 0.183
Yes 17 (63.0) 10 (37.0)
No 51 (46.4) 59 (53.6)
Chemotherapy
d 0.213
Yes 13 (65) 7 (35)
No 55 (47.0) 62 (53)
Pathogenic stage 0.807
I, II 39 (48.1) 42 (51.9)
III, IV 29 (51.8) 27 (48.2)
Differentiation 0.477
c
Poor 26 (53.1) 23 (46.9)
Moderate 39 (50.0) 39 (50.0)
Well 3 (30.0) 7 (70.0)
Tumor site 0.887
Rectum 42 (48.3) 45 (51.7)
Left colon 11 (50.0) 11 (50.0)
Right colon 15 (53.6) 13 (46.4)
a, No tobacco exposure was defined as never having smoked cigarettes daily for
more than 1 year.
b, No alcohol use was defined as never having consumed 1 drink or more per
month.
c, by Fisher’s exact test. d, Chemotherapy was used before surgery within 3
months.
doi:10.1371/journal.pone.0035900.t002
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from Invitrogen (Shanghai, China) and diluted to a concentration
of 10 mM. Hybridization was carried out at 45uC for 2 h. The
slides were washed in 26SSC/0.2% SDS at 42uC for 5 min, and
finally in ddH2Oa t4 2 uC for 5 min. The slides were dried by
centrifugation and scanned with a GenePix 4100 scanner (Axon,
Union, USA). Images were analyzed with GenePix Pro 5.0
software (Axon).
Quantitation of viral load by real-time PCR
A SYBR Green real-time PCR method was used to determine
JCV viral load in samples as described by Chapagain [22].
Specially, primers RT-JCT-F (59-AGA GTG TTG GGA TCC
TGT GTT TT-39) and RT-JCT-R (59-GAG AAG TGG GAT
GAA GAC CTG TTT-39) were used in the real-time PCR
targeting a sequence of T-antigen gene, producing a 78 bp
product during reaction. JCV viral load quantitation was
performed in the Bio-Rad CFX96 Real-time PCR Detection
System using 200 ng of template DNA, 10 ml of SYBR Green
PCR Master Mix (TaKaRa, Dalian, China) and 4 pmol each of
forward and reverse primers. Thermal cycling was initiated with
a first denaturation step at 95uC for 30 s, followed by 40 cycles of
95uC for 5 s and 60uC for 15 s and the amplification fluorescence
were monitored at 60uC at the end of each cycle. A standard curve
was constructed using serial dilutions (1.0 to 10
7 copies of JCV
DNA) of JCV T-antigen plasmid. Three replicates were performed
for each sample and real-time PCR data were analyzed using Bio-
Rad CFX manager software. The averaged copy numbers in
samples were calculated according to the standard curve and were
represent as copies of viral DNA per microgram genomic DNA.
Statistical methods
Demographic characteristics were compared between CRC
patients (C) and controls (non-CRC patients (N) or healthy donors
(H)) using the Student’s t-test for numeric variables and the x
2 test
for categorical variables. Sex, tobacco exposure, alcohol use,
residence, family history of CRC, pathogenic stage and tumor site
Figure 2. JCV viral load was higher in tumor tissues than in
non-cancerous tumor adjacent tissues and PB samples. JCV
positive samples determined by nested PCR were analyzed using qRT-
PCR. Blots represent averaged copy numbers (3 replicate wells) of JCV
DNA for tumor tissue, non-cancerous tissue and PB, respectively, and
bars represent calculated medians. P-values were calculated using the
Wilcoxon’s test.
doi:10.1371/journal.pone.0035900.g002
Table 3. Summary of the findings of JC virus studies in CRC patients.
Author and
reference citation Country Design
Positive
cases/total
cases
Prevalence
(%) Sample source
Detecting
method
Primers or region
amplified
Laghi et al. [11] USA Case 23/24 96 Fresh tissue Nested PCR T-antigen
Casini et al. [12] Italy Case 15/18 83.3 Paraffin-embedded
tissue
Southern blot,
PCR, ISH
T-antigen
Enam et al. [14] USA Case 22/27 81.4 Paraffin-embedded
tissue
PCR T-antigen,
agnoprotein
Goel et al. [24] USA Case 77/100 77 Paraffin-embedded
tissue
PCR T-antigen
Hori et al. [13] Japan Case-
control
6/23 26.1 Paraffin-embedded
tissue
Nested PCR T-antigen,
VP, agnoprotein
Lin et al. [23] Taiwan Case 19/22 86.4 Paraffin-embedded
tissue
Nested PCR T-antigen
Campello et al.
[25]
Italy Case-
control
0/94 0 Not known qRT-PCR T-antigen
Theodoropoulos
et al. [15]
Greece Case-
control
49/80 61.3 Paraffin-embedded
tissue and fresh
tissue
Nested PCR,
qRT-PCR
T-antigen
Newcomb et al.
[16]
USA Case 0/233 0 Paraffin-embedded
tissue
PCR, qRT-PCR T-antigen,
VP1, RR
Hernandez et al.
[17]
USA Case 1/100 1 Paraffin-embedded
tissue
PCR T-antigen
This study China Case-
control
47/98 48.0 Fresh tissue Nested PCR T-antigen
PCR, polymerase chain reaction; qRT-PCR: quantitative real-time PCR. ISH, in situ hybridization; VP, virus capsid protein; RR, regulator region.
doi:10.1371/journal.pone.0035900.t003
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using the x
2 test. Differentiation status was compared between
JCV-positive and -negative CRC patients using the Fisher’s exact
test. The exact logistic regression model, adjusted for age, was used
to estimate the association between JCV infection and CRC. R
statistical software (v 2.12.0, www.r-project.org/) was used for
statistical analysis. In all analyses, a P-value,0.05 was considered
statistically significant.
Results
Demographic characteristics of 137 CRC patients, 80 non-
CRC patients and 100 healthy donors are present in Table 1.
CRC patients were older than non-CRC patients (P,0.001), but
no difference was observed between CRC patients and healthy
donors. Family history of CRC was more common among CRC
patients verses non-CRC patients or healthy donors, but the
differences were not statistically significant (P=0.491 for C vs N,
P=0.162 for C vs H).
All samples were positive for the GAPDH control, indicating
adequate integrity of the samples. The negative controls in both
rounds of PCR revealed no evidence of reagent contamination.
Using nested PCR, the JCV T-antigen nucleotide sequence was
detected in 40.9% (56 of 137) of tumor tissues and 24.8% (34 of
137) of tumor-adjacent tissues from CRC patients (Figure 1). The
PCR products were confirmed as authentic JCV sequences by
glass-slide array analysis (Figure 1B). We found both matched
pairs of tumor tissue and non-cancerous tissue from 17.5% (24 of
137) of CRC patients were positive for JCV DNA. 23.4% (32 of
137) and 7.3% (10 of 137) of patients had JCV DNA only in tumor
tissue or non-cancerous tumor-adjacent tissue, respectively
(Figure 1C). 18.2% (25 of 137) of PB samples from CRC patients
were positive for JCV DNA. A significantly higher JCV presence
was observed in CRC tissues compared with non-cancerous
adjacent tissues (OR, 2.089; 95% CI, 1.213–3.636; P=0.007) and
PB samples (OR, 3.084; 95% CI, 1.729–5.619; P,0.001). JCV
presence in PB samples was positively associated with JCV status
in tissue samples (P,0.001); however, it was unrelated to patient
age, sex, tobacco exposure, alcohol use, residence, family history of
CRC, pathologic stage and tumor site but tended to increase with
the differentiation of CRC tissues, although this trend was not
statistical significant (Table 2). Compared with tissues from CRC
patients, only 13.8% (11 of 80) of colorectal tissues from non-CRC
patients had detectable JCV DNA. In the non-parameter statistical
analysis, JCV frequencies in CRC patients and non-CRC patients
were significantly different. Since the age of the two groups
differed, the association between JCV infection and CRC was
estimated by exact logistic regression analysis, adjusted for age.
The OR of JCV associated CRC risk was statistically significant
(OR, 6.611; 95% CI, 2.928–14.929; P,0.001). Among the PB
samples from 100 healthy volunteers, we found that only 7% (7 of
100) were positive for JCV DNA, which was lower than the JCV
positive percentage in PB samples from CRC patients (OR, 0.339;
95% CI, 0.118–0.852; P=0.021).
Viral load in JCV-positive samples from CRC patients were
determined by a quantitative real-time PCR (qRT-PCR). The
viral load in tumor tissues ranged from 49.15 to 1.03610
4 copies/
mg DNA (mean 6 SD, 3795.64 63054.58). Actually, the absolute
copy numbers for JCV DNA in CRC tumors were lower than 1
copy per cell. Low JCV viral load was observed in 34 JCV-
positive, non-cancerous, tumor-adjacent tissues (range, 192.85 to
4.44610
3 copies/mg DNA; mean 6 SD, 1470.096887.12) and 25
PB samples (range, 81.30 to 4962.99 copies/mg DNA; mean 6
SD, 945.1761140.39). Tumor tissues had significantly higher
levels of JCV DNA than non-cancerous tumor-adjacent tissues
and PB samples (Figure 2).
Discussion
In the present study, JCV was detected in 40.9% of CRC tissues
and 24.8% of non-cancerous colorectal tissues, which were in the
intermediate position of T-antigen rate in previous studies
(Table 3). Several potential reasons account for the lack of
agreement among these studies, including potential contamination
during sample collection and process during DNA extraction and
PCR amplification. Many studies did not report any step to
control false-positive results [11–12,14]. In the present study, we
avoided false-positive results as mentioned in our previous study
[21]. The sensitivity of the method is critical, as a low JCV viral
load in colorectal tissue has been documented [15]. Immunohis-
tochemistry, PCR, nested PCR and q-RT PCR have been used for
detecting JCV [11,14–15,23]. JCV DNA was detected in 1% and
0% of CRC tissues in two large studies [16–17] using a general
PCR assay, which is known to have lower sensitivity. Nested PCR
is a highly sensitive technique for detecting JCV. Smaller PCR
targets have been found to be more readily amplified than long
sequences for JCV detection [11]. As described by Hori et al. [13],
we used a nested PCR with primer sets targeting a 110 bp JCV T-
antigen sequence, which was able to detect as few as 1 copy of JCV
DNA (data not shown). It has been hypothesized the supercoiled
topology of the highly homologous JCV DNA might limit PCR
amplification efficiency [11]. However, we did not use topoisome-
rase I treatment before PCR amplification as described by Laghi et
al. [11], which may lead to a slightly lower rate of JCV infection.
Age, gender, region and lifestyle of a selected population could all
contribute to varying rates of JCV infection (Table 3). The
American CRC population was most commonly selected in
previous studies, in which JCV DNA was found in 0%–96% of
CRC tissues [11,14,16–17,24]. Contradictory results have been
reported by two Italian research groups [12,25]. Hori et al. [13]
and Lin et al. [23] identified JCV in 26.1% and 86.4%,
respectively, of CRC tissues from Asian populations. In our study,
JCV DNA was detected in 49.6% of Chinese CRC patients.
We further investigated the presence of JCV DNA in tissue from
non-CRC patients. In certain high-risk patients, such as those with
polyp or IBD, the incidence of CRC is substantially higher.
Therefore, patients undergoing colonoscopy for polyp and IBD
were excluded from the control cohort before sample collection.
Other than age, there was no baseline characteristic significantly
different between CRC and non-CRC patients. However,
adjustment for age did not change the association between JCV
infection and CRC. Combining with the observation of higher
prevalence of JCV in tumor tissue from CRC patients, we propose
that JCV is correlated with CRC and may participate in CRC
carcinogenesis or, alternatively, the virus infects tumor cells more
readily than non-cancerous cells.
In the present study, no correlation between the presence of
JCV and demographic or medical characteristics such as age,
gender, education, clinical stage, and tumor site was observed,
which was consistent with other studies [13,15]. Interestingly, we
found that tissues from CRC patients who received chemotherapy
prior to sample collection had higher incidence of JCV infection
compared with the patients without chemotherapy, although the
difference was not significant (Table 2). The association between
immunosuppression and increased susceptibility to infection is well
recognized. As demonstrated by Selgrad et al. [26] in a retrospec-
tive study among liver transplant recipients, Immunosuppressed
patients have a significantly higher presence of JCV compared
JC Virus and Colorectal Cancer in China
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the immune response and enable the reactivation of potentially
oncogenic viruses. CRC patients with a family history have
a higher prevalence of JCV T-Ag DNA, which is consistent with
the results described by Vilkin et al. [27]. JCV infection is usually
an asymptomatic infection and commonly occurs in later child-
hood and adolescence, after which the virus remains latent in the
kidney. Besides the immune condition mentioned above, genetic
background might also be associated with the susceptibility of JCV
infection in CRC.
The viral load in tissue samples could indicate the role of JCV in
CRC carcinogenesis. In the present study, JCV viral load in
positive samples from CRC patients were determined by q-RT
PCR. JCV viral copy numbers were found to be higher in tumor
tissues as compared with non-cancerous tumor adjacent tissues,
which is consistent with previous studies [11,15]. However, the
absolute copy numbers in tissues were so low that only a small part
of colorectal epithelial cells were found to be infected with JCV.
This result supports the transient effects of JCV in cellular
transformation, as it can be silenced or its genome can be lost
during cancer progression (‘‘hit-and-run’’ transformation) [28]. A
JCV infection introducing the T-antigen could easily explain the
onset of chromosomal instability in multistep carcinogenesis, such
as that previously proposed for the well-known adenoma-
carcinoma sequence [29].
To the best of our knowledge, this study is the first analysis of
JCV DNA in PB from CRC patients. We showed that JCV
infection is common in PB samples from CRC patients and
indicated JCV status in tissue samples. Unlike previous seroepi-
demiological studies, our results cannot be used to predict the risk
of CRC because all samples were collected within three months of
diagnosis [19–20]. Furthermore, the presence of JCV in PB of
CRC patients was higher than in PB of healthy donors. These
results supported the proposition that JCV DNA in PB samples
could be a valid biomarker for JCV-related CRC diagnosis.
However, medical characteristics of healthy donors were recorded
mainly through self-report which may lead to misclassification.
More importantly, JCV almost always remains latent in the kidney
and can be easily detected in urine [1–3]. Although the viral DNA
in bloodstream is widely considered to originate from cells shed
from tumor tissue, the origin of the JCV in PB samples remains
unknown.
In conclusion, JCV infection presents commonly in CRC
patients and might to be a risk factor for CRC. We suggest
ongoing molecular, cellular and in vivo studies to elucidate the
mechanisms of JCV carcinogenesis to determine whether JCV is
a causative agent of CRC. Although we found JCV DNA in PB
samples could serve as a biomarker for JCV-related CRC, further
large-scale population-based studies are encouraged to evaluate
this association.
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